Mirati Therapeutics Inc $ 123.77 -3.31 (-2.6%)
Volume:
121,494
Avg Vol (1m):
397,013
Market Cap $:
5.43 Bil
Enterprise Value $:
4.73 Bil
P/E (TTM):
0.00
P/B:
8.26
Financial Strength | 10/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Cash-To-Debt | No Debt | ||
| Equity-to-Asset | 0.92 | ||
| Interest Coverage | No Debt | ||
| Piotroski F-Score | 3 | ||
| Altman Z-Score | 56.37 | ||
| Beneish M-Score | -3.86 | ||
| WACC vs ROIC | |||
Profitability Rank |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Operating Margin % | -11400.98 | ||
| Net Margin % | -10980.87 | ||
| ROE % | -58.08 | ||
| ROA % | -53.34 | ||
| ROC (Joel Greenblatt) % | -24587.07 | ||
| 3-Year EBITDA Growth Rate | -11.9 | ||
| 3-Year EPS without NRI Growth Rate | -10.7 |
Valuation Rank |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| PB Ratio | 8.23 | ||
| PS Ratio | 2066.17 | ||
| EV-to-EBIT | -17.53 | ||
| EV-to-EBITDA | -17.56 | ||
| EV-to-Revenue | 1999.57 | ||
| Current Ratio | 12.58 | ||
| Quick Ratio | 12.58 |
Dividend & Buy Back |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -25.6 |
Valuation & Return |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Price-to-Tangible-Book | 8.23 | ||
| Earnings Yield (Greenblatt) % | -5.7 |